Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.12
+0.06000.50%
Post-market: 12.180.0600+0.50%16:28 EDT
Volume:7.44M
Turnover:91.42M
Market Cap:1.70B
PE:-3.62
High:12.66
Open:11.98
Low:11.82
Close:12.06
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.74
T/O Rate:5.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.33
PE(LYR):-3.18

Loading ...

Intellia Therapeutics Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

High Growth Tech Stocks In The US For May 2026

Simply Wall St.
·
May 13

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

TIPRANKS
·
May 13

Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline

Simply Wall St.
·
May 13

Intellia Therapeutics Price Target Maintained With a $12.00/Share by Wedbush

Dow Jones
·
May 12

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
May 12

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

TIPRANKS
·
May 12

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

TIPRANKS
·
May 12

Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Intellia Therapeutics Q1 Loss Narrows, Revenue Falls

MT Newswires Live
·
May 11

Intellia Therapeutics Q1 net loss narrows on lower R&D spending

Reuters
·
May 11

Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate

Benzinga Earnings
·
May 11

Earnings Flash (NTLA) Intellia Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.91 Loss

MT Newswires Live
·
May 11

BRIEF-Intellia Therapeutics Q1 Net Income USD -96.231 Million

Reuters
·
May 11

Intellia Q1 FY26 net loss narrows 15.9% to $96.2 million

Reuters
·
May 11

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

THOMSON REUTERS
·
May 11

Intellia Therapeutics Q1 Basic EPS USD -0.81

THOMSON REUTERS
·
May 11